Cantor Fitzgerald Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $74
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $74.
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $74.